Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline Review, H2 2017’, provides an overview of the Methicillin-Resistant Staphylococcus aureus (MRSA) Infections pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Methicillin-Resistant Staphylococcus aureus (MRSA) Infections

The report reviews pipeline therapeutics for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Methicillin-Resistant Staphylococcus aureus (MRSA) Infections therapeutics and enlists all their major and minor projects

The report assesses Methicillin-Resistant Staphylococcus aureus (MRSA) Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Methicillin-Resistant Staphylococcus aureus (MRSA) Infections pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AbbVie Inc

Absynth Biologics Ltd

Actelion Pharmaceuticals Ltd

Adenium Biotech ApS

Alchemia Ltd

Allergan Plc

AmpliPhi Biosciences Corp

Antibiotx ApS

Aphios Corp

Aridis Pharmaceuticals LLC

Atriva Therapeutics GmbH

Bavarian Nordic A/S

Bharat Biotech International Ltd

C3J Therapeutics Inc

Cadila Pharmaceuticals Ltd

Citius Pharmaceuticals Inc

Common Pharma Inc

ContraFect Corp

Crestone Inc

Critical Outcome Technologies Inc

CrystalGenomics Inc

Daiichi Sankyo Co Ltd

Debiopharm International SA

Dermala Inc

DesignMedix Inc

Destiny Pharma Ltd

Dong-A Socio Holdings Co Ltd

Emergent BioSolutions Inc

Ensol Biosciences Inc

GangaGen Inc

GlaxoSmithKline Plc

Helix BioMedix Inc

Helperby Therapeutics Group Ltd

Hsiri Therapeutics LLC

Ildong Pharmaceutical Co Ltd

Immupharma Plc

iNtRON Biotechnology Inc

ioGenetics Inc

Kyorin Pharmaceutical Co Ltd

Lakewood-Amedex Inc

Lead Discovery Center GmbH

LegoChem Biosciences Inc

Lipocure Ltd

Madam Therapeutics BV

Melinta Therapeutics Inc

Merck & Co Inc

Microbiotix Inc

MicuRx Pharmaceuticals Inc

MorphoSys AG

Nabriva Therapeutics plc

Nemus Bioscience Inc

Novabiotics Ltd

NovaDigm Therapeutics Inc

Novalex Therapeutics Inc

Novan Inc

NovoBiotic Pharmaceuticals LLC

Oragenics Inc

Ovensa Inc

Pfizer Inc

Phico Therapeutics Ltd

PolyPid Ltd

Prommune Inc

Recce Ltd

Savara Inc

Sealife PHARMA GMBH

Sorrento Therapeutics Inc

Taejoon Pharm Co Ltd

TAXIS Pharmaceuticals Inc

Telephus Medical LLC

Tetraphase Pharmaceuticals Inc

Theravance Biopharma Inc

Trellis Bioscience Inc

Valevia UK Ltd

Venus Medicine Research Center

VLP Biotech Inc

Wockhardt Ltd

XBiotech Inc

Yungjin Pharm Co Ltd

Table of Contents

Table of Contents

Table of Contents 2

Introduction 6

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Overview 7

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Therapeutics Development 8

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Therapeutics Assessment 30

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Companies Involved in Therapeutics Development 40

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Drug Profiles 75

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Dormant Projects 330

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Discontinued Products 338

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Product Development Milestones 339

Appendix 350

List of Tables

List of Tables

Number of Products under Development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections, H2 2017 26

Number of Products under Development by Companies, H2 2017 28

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017 29

Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017 30

Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017 31

Number of Products under Development by Companies, H2 2017 (Contd..4), H2 2017 32

Number of Products under Development by Companies, H2 2017 (Contd..5), H2 2017 33

Number of Products under Development by Universities/Institutes, H2 2017 34

Number of Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017 36

Products under Development by Companies, H2 2017 37

Products under Development by Companies, H2 2017 (Contd..1), H2 2017 38

Products under Development by Companies, H2 2017 (Contd..2), H2 2017 39

Products under Development by Companies, H2 2017 (Contd..3), H2 2017 40

Products under Development by Companies, H2 2017 (Contd..4), H2 2017 41

Products under Development by Companies, H2 2017 (Contd..5), H2 2017 42

Products under Development by Companies, H2 2017 (Contd..6), H2 2017 43

Products under Development by Companies, H2 2017 (Contd..7), H2 2017 44

Products under Development by Universities/Institutes, H2 2017 45

Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017 46

Products under Development by Universities/Institutes, H2 2017 (Contd..2), H2 2017 47

Number of Products by Stage and Target, H2 2017 49

Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017 50

Number of Products by Stage and Mechanism of Action, H2 2017 52

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017 53

Number of Products by Stage and Route of Administration, H2 2017 55

Number of Products by Stage and Molecule Type, H2 2017 57

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by AbbVie Inc, H2 2017 58

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Absynth Biologics Ltd, H2 2017 59

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Actelion Pharmaceuticals Ltd, H2 2017 59

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Adenium Biotech ApS, H2 2017 60

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Alchemia Ltd, H2 2017 60

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Allergan Plc, H2 2017 61

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by AmpliPhi Biosciences Corp, H2 2017 61

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Antibiotx ApS, H2 2017 62

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Aphios Corp, H2 2017 62

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Aridis Pharmaceuticals LLC, H2 2017 62

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Atriva Therapeutics GmbH, H2 2017 63

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Bavarian Nordic A/S, H2 2017 63

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Bharat Biotech International Ltd, H2 2017 64

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by C3J Therapeutics Inc, H2 2017 64

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Cadila Pharmaceuticals Ltd, H2 2017 65

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Citius Pharmaceuticals Inc, H2 2017 65

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Common Pharma Inc, H2 2017 65

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by ContraFect Corp, H2 2017 66

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Crestone Inc, H2 2017 66

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Critical Outcome Technologies Inc, H2 2017 67

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by CrystalGenomics Inc, H2 2017 67

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Daiichi Sankyo Co Ltd, H2 2017 68

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Debiopharm International SA, H2 2017 68

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Dermala Inc, H2 2017 68

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by DesignMedix Inc, H2 2017 69

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Destiny Pharma Ltd, H2 2017 69

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Dong-A Socio Holdings Co Ltd, H2 2017 70

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Emergent BioSolutions Inc, H2 2017 70

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Ensol Biosciences Inc, H2 2017 71

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by GangaGen Inc, H2 2017 71

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by GlaxoSmithKline Plc, H2 2017 72

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Helix BioMedix Inc, H2 2017 72

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Helperby Therapeutics Group Ltd, H2 2017 72

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Hsiri Therapeutics LLC, H2 2017 73

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Ildong Pharmaceutical Co Ltd, H2 2017 73

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Immupharma Plc, H2 2017 74

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by iNtRON Biotechnology Inc, H2 2017 74

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by ioGenetics Inc, H2 2017 75

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Kyorin Pharmaceutical Co Ltd, H2 2017 75

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Lakewood-Amedex Inc, H2 2017 75

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Lead Discovery Center GmbH, H2 2017 76

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by LegoChem Biosciences Inc, H2 2017 76

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Lipocure Ltd, H2 2017 77

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Madam Therapeutics BV, H2 2017 77

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Melinta Therapeutics Inc, H2 2017 78

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Merck & Co Inc, H2 2017 78

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Microbiotix Inc, H2 2017 79

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by MicuRx Pharmaceuticals Inc, H2 2017 79

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by MorphoSys AG, H2 2017 80

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Nabriva Therapeutics plc, H2 2017 80

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Nemus Bioscience Inc, H2 2017 80

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Novabiotics Ltd, H2 2017 81

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by NovaDigm Therapeutics Inc, H2 2017 81

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Novalex Therapeutics Inc, H2 2017 82

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Novan Inc, H2 2017 82

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by NovoBiotic Pharmaceuticals LLC, H2 2017 82

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Oragenics Inc, H2 2017 83

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Ovensa Inc, H2 2017 83

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Pfizer Inc, H2 2017 84

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Phico Therapeutics Ltd, H2 2017 84

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by PolyPid Ltd, H2 2017 85

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Prommune Inc, H2 2017 85

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Recce Ltd, H2 2017 85

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Savara Inc, H2 2017 86

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Sealife PHARMA GMBH, H2 2017 86

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Sorrento Therapeutics Inc, H2 2017 87

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Taejoon Pharm Co Ltd, H2 2017 87

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by TAXIS Pharmaceuticals Inc, H2 2017 88

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Telephus Medical LLC, H2 2017 88

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Tetraphase Pharmaceuticals Inc, H2 2017 89

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Theravance Biopharma Inc, H2 2017 89

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Trellis Bioscience Inc, H2 2017 90

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Valevia UK Ltd, H2 2017 90

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Venus Medicine Research Center, H2 2017 90

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by VLP Biotech Inc, H2 2017 91

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Wockhardt Ltd, H2 2017 91

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by XBiotech Inc, H2 2017 92

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Yungjin Pharm Co Ltd, H2 2017 92

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Dormant Projects, H2 2017 348

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Dormant Projects, H2 2017 (Contd..1), H2 2017 349

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Dormant Projects, H2 2017 (Contd..2), H2 2017 350

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Dormant Projects, H2 2017 (Contd..3), H2 2017 351

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Dormant Projects, H2 2017 (Contd..4), H2 2017 353

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Dormant Projects, H2 2017 (Contd..5), H2 2017 355

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Discontinued Products, H2 2017 356

List of Figures

List of Figures

Number of Products under Development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections, H2 2017 26

Number of Products under Development by Companies, H2 2017 27

Number of Products under Development by Universities/Institutes, H2 2017 34

Number of Products by Top 10 Targets, H2 2017 48

Number of Products by Stage and Top 10 Targets, H2 2017 48

Number of Products by Mechanism of Actions, H2 2017 51

Number of Products by Stage and Mechanism of Actions, H2 2017 51

Number of Products by Routes of Administration, H2 2017 54

Number of Products by Stage and Routes of Administration, H2 2017 54

Number of Products by Top 10 Molecule Types, H2 2017 56

Number of Products by Stage and Top 10 Molecule Types, H2 2017 56

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports